AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological research, announced today that its acquiree Sapphire Biotech, Inc. (“Sapphire”) has signed an agreement with Skysong Innovations, LLC (“SI”) to exclusively license rights to pharmaceutical compositions and methods for the treatment of cancer.
SI, the intellectual property management company for Arizona State University (“ASU”), licensed the Patents, Technical Information and Materials (“Technology”) to Sapphire on behalf of SI and Mayo Clinic.
The Technology was developed in the laboratory of Sapphire co-founder, Douglas Lake, Ph.D, Associate Professor at Arizona State University with an adjunct appointment at Mayo Clinic. After extensive testing, Dr. Lake discovered that QSOX1 promotes cancer invasion by remodeling the extracellular matrix (ECM) that serves as an adhesive surface to tumor cells.
Working together with Drs. Faigel and Ho at Mayo Clinic, Dr. Lake discovered that a certain compound, SBI-183, selectively targets QSOX1 (Quiescin Sulfhydryl Oxidase 1), an enzyme important for tumor cell growth, invasion and metastasis. In animal models, the Lake Laboratory found that SBI-183 inhibits tumor growth, invasion and suppresses metastasis of tumors by inactivating QSOX1.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“Sapphire is excited to develop a potential therapeutic treatment for multiple cancers that over-express QSOX1. Such tumors include breast, bladder, brain, colorectal, lung, liver, lymphoma, pancreatic, and prostate cancers. Our drug development efforts will be aimed at disabling this key enzyme which is involved in the replication of tumor cells,” said Catalina Valencia, Chief Executive Officer of Sapphire Biotech.
“AXIM Biotechnologies found Sapphire’s therapeutic approach for the treatment of cancer novel, and this was a compelling reason for acquiring the company,” said John H. Huemoeller II, Chief Executive Officer of AXIM® Biotech. “There is no more significant goal in developing a drug than saving lives, and, for this reason, AXIM is committed to support and be part of Sapphire’s mission.”
Source: Biospace